Skip to main content

Treatment Clinical Trials for Gastric (Stomach) Cancer

Review the gastric (stomach) cancer treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 76-100 of 153

A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
Status: Active
Location: 2 locations
A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
Status: Active
Location: 2 locations
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
Status: Active
Location: 2 locations
Image Guided Radiation Therapy with MRI for the Treatment of Cancer, CONFIRM Study
Status: Active
Location: 2 locations
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Status: Active
Location: 2 locations
Evaluating Response to Atezolizumab and Bevacizumab Treatment in Patients with Gastrointestinal Cancers and Minimal Residual Disease using ctDNA
Status: Active
Location: MedStar Georgetown University Hospital, Washington, District of Columbia
Comparing Length of Treatment with Immunotherapy in Patients with Advanced Solid Tumors
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Local Consolidative Therapy to Extend the Efficacy of Systemic Therapy in Oligoprogressive Metastatic Cancer, EXTEND-OP Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Pyrvinium for the Treatment of Gastric Intestinal Metaplasia in Patients Previously Treated for Helicobacter Pylori Infection, REVISE Trial
Status: Active
Location: Duke University Medical Center, Durham, North Carolina
Hyperthermic Intraperitoneal Chemotherapy with Cisplatin and Paclitaxel for the Treatment of Patients with Gastric and Gastroesophageal Junction Adenocarcinoma at High Risk of Peritoneal Recurrence
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Stomach Cancer with Peritoneal Metastases
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Avutometinib with Defactinib for the Treatment of Patients with Metastatic Diffuse Gastric Cancer
Status: Active
Location: NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York
Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Gastric Cancer with Limited Peritoneal Metastasis, ROBO-CHIP Study
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Neratinib in Combination with Chemotherapy, Trastuzumab, Pembrolizumab in Patients with Stage HER2 Overexpressing Stage IV Gastroesophageal Cancers
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Tadalafil in Combination with FLOT Chemotherapy prior to Surgery for the Treatment of Stage I-III Resectable Gastric/Gastroesophageal Junction Cancer
Status: Active
Location: Banner University Medical Center - Tucson, Tucson, Arizona
Chemotherapy with or without Radiation or Surgery in Treating Participants with Oligometastatic Esophageal or Gastric Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Perioperative Intraperitoneal Paclitaxel for the Treatment of Stage IV Gastric or Gastroesophageal Adenocarcinoma with Carcinomatosis or Positive Cytology
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma
Status: Active
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers
Status: Active
Location: 2 locations
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Immunotherapy (Pembrolizumab or Nivolumab) with Metformin or Rosiglitazone for the Treatment of Advanced Solid Tumors
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Cell Therapy for the Treatment of Locally Advanced, Metastatic, or Recurrent Solid Cancers
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
Status: Active
Location: UC San Diego Moores Cancer Center, La Jolla, California